Lobe Sciences Ltd.
LOBE
CNSX
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -100.00% | -84.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -100.00% | -84.18% |
| Cost of Revenue | -- | 219.50% | -46.11% | -46.11% | -35.00% |
| Gross Profit | -- | -120.62% | -101.46% | -101.46% | -85.62% |
| SG&A Expenses | 94.23% | 1.71% | -23.57% | -29.22% | -38.92% |
| Depreciation & Amortization | -- | -100.00% | -71.64% | -20.42% | 91.41% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.30% | -19.94% | -38.34% | -44.76% | -46.74% |
| Operating Income | -91.78% | -10.47% | 14.96% | 26.59% | 37.29% |
| Income Before Tax | -8.90% | -91.29% | -74.27% | -49.13% | 3.96% |
| Income Tax Expenses | -- | -84.33% | -84.33% | -84.33% | -84.33% |
| Earnings from Continuing Operations | -8.09% | -79.04% | -62.78% | -40.65% | 7.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.60% | -74.18% | -62.78% | -40.65% | 7.49% |
| EBIT | -91.78% | -10.47% | 14.96% | 26.59% | 37.29% |
| EBITDA | -95.69% | -12.86% | 14.35% | 27.45% | 38.99% |
| EPS Basic | -296.99% | -789.55% | -817.01% | -669.79% | -363.96% |
| Normalized Basic EPS | -1,122.49% | -200.00% | -199.15% | -157.75% | -117.24% |
| EPS Diluted | -296.99% | -789.55% | -817.01% | -669.79% | -363.96% |
| Normalized Diluted EPS | -1,122.49% | -200.00% | -199.15% | -157.75% | -117.24% |
| Average Basic Shares Outstanding | 94.82% | 31.09% | 12.88% | -11.52% | -32.22% |
| Average Diluted Shares Outstanding | 94.82% | 31.09% | 12.88% | -11.52% | -32.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |